An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Study Data Support Efficacy of Treatment for Vasomotor Symptoms Associated with Menopause As reported in the Sept. 6 Pharma Fridays, Bayer will present detailed results from the Phase III study OASIS 3, providing supporting efficacy data and sustained safety data over...
Bills, Bills, Bills: Tips for Navigating the Revenue Landscape
On the Basis of Sex: The Ongoing Efforts to Fund Women’s Health Research
Monica M. Laronda, PhD, and Jane E. Reusch, MD, have long been leading advocates for the importance of equity in scientific research, specifically as it relates to women’s health. As they engage with national initiatives focusing on how this research is funded, they spoke to Endocrine News to discuss the latest in these efforts, their...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Glytec Expands Global Collaboration with Roche to Revolutionize Hospital Diabetes Management Transforming Global Hospital Diabetes Management On August 27, Glytec, announced an expansion of its collaboration with Roche, that will allow the use of Glytec’s software in connection with Roche’s smart-device...
Pregnant Women Exposed to PFAS May Be at Risk for Obesity, Heart Disease Later in Life
Women with higher levels of per- and polyfluoroalkyl substances (PFAS) during pregnancy may experience long-term weight gain and heart problems later in life, according to new research published in The Journal of Clinical Endocrinology & Metabolism. PFAS are manmade chemicals found in food packaging, cookware, clothes, drinking water, personal care products and many other consumer goods. These endocrine-disrupting...